2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Serologic Tests, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Checkpoint Inhibitor, Immunotherapy, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1824 Rearranged immunoglobulin-encoding ctDNA, CCL17, CCL22 and sCD30 are sensitive plasma biomarkers predictive of treatment response in patients with classic Hodgkin lymphoma treated on modern chemoimmunotherapy protocols

Ilia N Buhtoiarov, MD, Brian Hill, MD, PhD2, Daniel Lindner, MD, PhD3, Ilan Kirsch, MD, PhD4, Seth Rotz, MD5, Deepa Jagadeesh, MD, MPH6, Paolo Fabrizio Caimi, MD7, Omer Koc, MD8, Robert Dean, MD9, Rabi Hanna, MD10
1 Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Adaptive Biotechnologies, Seattle, Washington, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
7 Cleveland Clinic Foundation, Cleveland, Ohio, United States
8 Cleveland Clinic Foundation, Cleveland, Ohio, United States
9 Cleveland Clinic Foundation, Cleveland, Ohio, United States
10 Cleveland Clinic Foundation, Cleveland, Ohio, United States

Introduction: Longitudinal assessment of the plasma-derived tumor-specific biomarkers including circulating tumor DNA (ctDNA) and cytokine levels is a potentially useful tool for assessment of treatment response and recurrence in patients classical Hodgkin lymphoma (cHL). Specifically, ctDNA encoding rearranged immunoglobulin (Ig) heavy or light chain specific to Hodgkin/Reed-Sternberg cells (rlg-ctDNA) has been demonstrated to be a trackable surrogate for disease burden. Little is known about the correlation and performance of ctDNA and cytokine biomarkers in this setting.

Methods: We studied the prognostic correlation between known cHL biomarkers such as CCL17, CCL22, soluble CD25 (sCD25), sCD30, CD163, IL10, IL1Rα, rIg-ctDNA, and functional imaging by 18FDGPET for cHL patients treated on modern chemoimmunotherapy protocols. Pre-treatment (pre-Tx) plasma and diagnostic biopsy samples from cHL patients were tested for presence of concordant dominant rIg-ctDNA sequences. Sequence dominance and suitability for tracking was determined according to the Adaptive Biotechnology diagnostic algorithm. If dominant rIg-ctDNA sequence was detected, the patient plasma was serially tested at baseline, at the end of cycle 2 (EOC2), and at the end of therapy (EOT). Plasma concentration of the cytokine biomarkers was measured by custom xMAP bead-based multiplexed assay (ProcartaPlex)/Luminex platform.

Patients: Twenty patients (F=14; M=6; age 14-29y; median 21y) were prospectively enrolled. Five patients had early-stage favorable (EF; stage I-IIA) cHL; 5 – early-stage unfavorable (EUF; stage IIB±bulk); 10 - advanced (ADV; stage III-IV) cHL, based on Ann Arbor/EORTC classification.

Pre-Tx plasma was available from all 20 patients. Three patients were deemed ineligible for longitudinal rIg-ctDNA testing due to steroid treatment before main therapy. Pre-Tx plasma samples from 2 patients were exhausted by testing for rIg-ctDNA. Thus, pre-Tx plasma from 18 patients was assayed for the tumor biomarkers. Dominant trackable rIg-ctDNA was detected in 13 patients (76%).  Plasma from 10 patients was prospectively collected. All enrolled patients underwent treatment response evaluation by 18FDGPET at EOC2 and EOT.

Of the 10 patients who completed longitudinal monitoring, 3 patients were treated on ABVD-based chemotherapy alone; 2 – ABVD-based regimen plus brentuximab vedotin (BV); 4 - ABVD-based regimen plus nivolumab (NIVO); 1 - ABVD-based regimen plus BV and NIVO. Eight patients achieved complete metabolic remission (CMR) at EOC2; 2 patients demonstrated partial response and required therapy intensification. All treated patients achieved complete response at EOT. EFS at 24 months follow up was 100%.

Results: Plasma levels of CCL17, CCL22, sCD25, sCD30, CD163, IL10, IL1Rα, and rIg-ctDNA were elevated at the time of the diagnosis and were similar between EF, EUF and ADV patient groups (ordinary one-way ANOVA p>0.096). Changes of only rIg-ctDNA, CCL17, CCL22 and sCD30 directly correlated with the treatment-induced clinical course and imaging findings (ANOVA p<0.03). Reduction in these biomarker plasma concentration by 90% (student t-test p<0.03) from pre-Tx level was observed at EOC2, when 8/10 patients were found to be in CMR by 18FDGPET. CCL17 concentration at EOC2 was statistically different (mean ± st.err: 504 ± 61 vs 37.1 ± 5.4 ng/mL, p<0.00001) between group of patients who were not in CRM and some patients with AVD cHL (n=4), vs group of patients with EF and EUF cHL (n=6). Notably, rIg-ctDNA became below analytical threshold of detection at EOC2 in all but one patient with EF cHL (stage IIA) who demonstrated incomplete response to initial ABVD therapy, and needed therapy escalation to BEACOPP x 2 followed by IFRT. The rIg-ctDNA levels were undetectable at EOT in all 10 patients, and correlated well with EOT 18FDGPET findings. The rIg-ctDNA levels remained undetectable at 24 months follow up.

Conclusions:  Hodgkin/Reed-Sternberg cell-derived rIg-ctDNA, CCL17, CCL22 and sCD30 are sensitive indicators of the therapy-induced antitumor effect. Both rIg-ctDNA and CCL17 remained quantifiable in patients with incomplete response at EOC2, which could be of prognostic value in cases when functional imaging by 18FDGPET is not available. The therapy with NIVO, the immune check-point inhibitor, or BV, the antibody-drug conjugate, did not affect the dynamics of biomarker concentration changes.
Ilia N Buhtoiarov, MD: No relevant conflicts of interest to declare.